June 2, 2026 -- SMi Systems announces today the execution of a non-exclusive evaluation collaboration with Luminex Corporation to assess the feasibility of using Luminex beads with SMi's single-molecule imaging platform and to compare SMi's analytical sensitivity with Luminex's current xMAP readers under defined test conditions. The evaluation is initially focused on research activities to validate the potential for SMi's technology to complement Luminex's industry leading xMAP technology. SMi

Study Results Demonstrated Favorable Safety Profile and Preliminary Signals of Clinical Activity June 2, 2026 -- Evogene Ltd. ("Evogene") (Nasdaq: EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in generative design of small molecules for the pharmaceutical and agricultural industries, today announced the successful completion of the first-in-human (FIH) Phase 1 clinical study of BMC128, a rationally-designed live bacterial product developed by its subsidiary, Biom

AQUIPTA® (atogepant) is now approved in the European Union for the acute treatment of migraine in adults, with or without aura, and for the prophylaxis of migraine in adults who have at least four migraine days per month. Approval was based on the pivotal Phase 3 ECLIPSE trial, which showed that AQUIPTA resulted in statistically significant pain freedom at two hours versus placebo during the first migraine attack, with sustained pain freedom from 2 to 48 hours and a clinically meaningful and con

China’s NMPA has granted marketing approval to eratrectinib (VC004), a next-generation TRK inhibitor developed by Nanjing-based Jiangsu Vcare PharmaTech Co., Ltd., for adult and adolescent patients with advanced solid tumors harboring NTRK gene fusions. The tumor-agnostic approval is notable for extending coverage to patients who have progressed on first-generation TRK inhibitors — a population for whom treatment options remain limited — and represents the first domestically developed next-gener

Two regimens containing Celcuity's multi-target PAM inhibitor gedatolisib halved the risk of disease progression or death versus Novartis' PI3Kα inhibitor Piqray (alpelisib) in adults with hormone receptor (HR)-positive, HER2-negative, PIK3CA mutated, locally advanced or metastatic breast cancer. The statistically significant and clinically meaningful findings come from the Phase III VIKTORIA-1 trial, which were presented Tuesday at the American Society of Clinical Oncology (ASCO) annual meeting

Emi-Le recently received Breakthrough Designation from the U.S. Food and Drug Administration (FDA) for the proposed treatment of patients with locally advanced, recurrent or metastatic ACC with solid histology or high-grade transformation Oral presentation shows Emi-Le was well tolerated and showed promising signals of efficacy among 45 evaluable participants with ACC June 1, 2026 -- Servier today announced promising new Phase 1 clinical data for Emi-Le, an investigational antibody drug conjuga

ZAYNICH is a multi- penicillin-binding protein targeting combination of the 4th generation cephalosporin cefepime and zidebactam working synergistically against the most challenging multidrug-resistant Gram-negative bacteria In the Phase 3 ENHANCE-1 clinical trial, ZAYNICH demonstrated higher combined clinical cure and microbiologic response (composite endpoint) at the test of cure (TOC) visit versus meropenem, 89.0% vs 68.4% respectively and was generally well tolerated More than 2.8 million an

June 1, 2026 -- SystImmune, Inc., a clinical-stage biotechnology company, today announced the oral presentation of Phase 1 data for BL-M14D1 in patients with small-cell lung cancer (SCLC), neuroendocrine carcinoma (NEC), and other solid tumors (BL-M14D1-101, NCT06505824) at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting in Chicago. BL-M14D1 is a DLL3 targeting antibody drug conjugate being developed globally by SystImmune, a subsidiary of Biokin. This study evaluated the

Servier has agreed to acquire Edgewise Therapeutics' muscular dystrophy business for up to $2.65 billion, gaining control of the latter's late-stage candidate sevasemten. The move comes on the heels of the French drugmaker's roughly $2.5-billion takeout of Day One Biopharmaceuticals earlier this year. Monday's transaction includes $1.55 billion in upfront cash and as much as $1.1 billion in regulatory and commercial milestones. Expected to close in the third quarter, the deal transfers to Servi

The EGFR-NSCLC pipeline possesses some drugs in late-stage development to be approved in the near future. The emerging landscape holds a diverse range of therapeutic alternatives for treatment, including Zipalertinib (CLN-081) (Cullinan Oncology/Taiho Pharma), Firmonertinib (ArriVent BioPharma), Ivonescimab (SMT112) (Akeso Biopharma/Summit Therapeutics), PF-08046054 (Pfizer), Patritumab Deruxtecan (Daiichi Sankyo/AstraZeneca), Sacituzumab Tirumotecan (MK-2870) (Merck/Kelun-Biotech), SYS6010 (CSP